Observational report examines COVID-19 antiviral treatment patterns in US older adults

This observational report analyzed data from the National Patient-Centered Clinical Research Network in the United States. The study population consisted of older adults aged 65 years and older with a COVID-19 diagnosis, though the exact sample size was not reported. The exposure of interest was receipt of a recommended COVID-19 antiviral medication, with no specific comparator group identified.

The primary outcome was the percentage of older adults with a COVID-19 diagnosis who received a recommended COVID-19 antiviral medication. However, the report did not provide the actual percentage, effect sizes, absolute numbers, or statistical measures for this outcome. The direction of any findings and specific results by age group were also not reported.

No safety or tolerability data were provided in the report. Key limitations include the observational nature of the data, which cannot establish causality, and the absence of reported results for the primary outcome measure. The practice relevance of these findings is limited until more complete data become available, though the report suggests potential treatment disparities warrant further investigation in this vulnerable population.